Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier L Chinot

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|August 29, 2014
Cilengitide in glioblastoma: when did it fail?Olivier L Chinot
Seminars in Oncology|February 7, 2004
Should radiotherapy be standard therapy for brain tumors in the elderly? ConsOlivier L Chinot
Expert Review of Anticancer Therapy|December 20, 2012
Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to dateOlivier L Chinot
The New England Journal of Medicine|May 27, 2014
Bevacizumab for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Timothy Cloughesy
Seminars in Oncology|February 7, 2004
Treatment of primary central nervous system lymphoma in the elderlyKhê Hoang-Xuan, Olivier L Chinot, Luc Taillandier
Oncotarget|February 23, 2018
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trialMogens K Boisen, Camilla B Holst, Nicola Consalvo, et al.
Current Neurology and Neuroscience Reports|March 27, 2013
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapyOlivier L Chinot, David R Macdonald, Lauren E Abrey, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Neuro-Oncology|January 27, 2016
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapyFrank Saran, Olivier L Chinot, Roger Henriksson, et al.
Neuro-Oncology|March 24, 2016
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglioOlivier L Chinot, Ryo Nishikawa, Warren Mason, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|August 29, 2014
Cilengitide in glioblastoma: when did it fail?Olivier L Chinot
Seminars in Oncology|February 7, 2004
Should radiotherapy be standard therapy for brain tumors in the elderly? ConsOlivier L Chinot
Expert Review of Anticancer Therapy|December 20, 2012
Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to dateOlivier L Chinot
The New England Journal of Medicine|May 27, 2014
Bevacizumab for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Timothy Cloughesy
Seminars in Oncology|February 7, 2004
Treatment of primary central nervous system lymphoma in the elderlyKhê Hoang-Xuan, Olivier L Chinot, Luc Taillandier
Oncotarget|February 23, 2018
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trialMogens K Boisen, Camilla B Holst, Nicola Consalvo, et al.
Current Neurology and Neuroscience Reports|March 27, 2013
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapyOlivier L Chinot, David R Macdonald, Lauren E Abrey, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Neuro-Oncology|January 27, 2016
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapyFrank Saran, Olivier L Chinot, Roger Henriksson, et al.
Neuro-Oncology|March 24, 2016
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglioOlivier L Chinot, Ryo Nishikawa, Warren Mason, et al.
Pageof 4